Page 12 - Therapeutics Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article ResearchAndMarkets.com's offering. microRNA 21 (MIR21) - Drugs in Development, 2021 provides in depth analysis on microRNA 21 (MIR21) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview o...

Global Therapeutic Landscape of Avian Influenza Drugs in Development 2021 News provided by Share this article Share this article ResearchAndMarkets.com's offering. Avian Influenza (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Avian Influenza, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action o...

Search jobs 22-Apr-2021 Aptamers Market 2021: Impact Of Covid-19, Challenges, Business Overview and Forecast Research Study 2027 | AM Biotechnologies, LLC, Aptagen, LLC, Aptamer Sciences, Inc. & so on… Future Market Insights (FMI) adopted a multidisciplinary approach during the pandemic-era to focus on the growth and development of the Aptamers Market. The study features insights on the current growth dynamics and the major revenue reforms prevailing in the market as of 2020 along with the key takeaways over the forecast period.   Impact of COV...

BESREMi® (Ropeginterferon alfa-2b) deemed safe and efficacious by the US FDA BESREMi® (Ropeginterferon alfa-2b) deemed safe and efficacious by the US FDA Wien (pts026/15.03.2021/15:15) - The US Food & Drug Administration (FDA) issued a complete response letter for the drug BESREMi® with the active pharmaceutical ingredient Ropeginterferonalfa-2b, in which the FDA confirms the efficacy and safety of the drug. This assessment was based on the clinical development program by the European rare disease company AOP Orphan. On March 12, 2021, according to PharmaEssentia Corp., the FDA in the...

Share this article Share this article CLEVELAND, March 3, 2021 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2021 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer's disease or related dementias. The Request for Proposal (RFP) is open to academic investigators at accredited medical centers, research institutions, and universities in the United...